Is ASND or ATOS more undervalued in 2026?

CirclFi compares Ascendis Pharma A/S (ASND) and Atossa Therapeutics, Inc. (ATOS) using 13 institutional-grade valuation models. ASND has a Quality of Company score of 5.9/10 while ATOS scores 4.5/10.

Which is a better buy — ASND or ATOS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ASND and ATOS valuations compare?

ASND at $237.47 and ATOS at $5.19 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ASND vs ATOS Valuation Comparison 2026 — Intrinsic Value Analysis

ASND

Biotechnology

Ascendis Pharma A/S

Quality

5.9

out of 10

Value Trap

SAFE

Price

$237.47

Last close

Models

12/13

Active

ATOS

Biotechnology

Atossa Therapeutics, Inc.

Quality

4.5

out of 10

Value Trap

SAFE

Price

$5.19

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	ASND Fair Value	ASND Upside	ATOS Fair Value	ATOS Upside
Bayesian DCF	Intrinsic	$69.36	-70.8%	$3.40	-34.4%
Earnings Power Value	Intrinsic	$7.22	-96.7%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$22.16	-90.7%	$0.52	-90.2%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ASND vs ATOS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ASND vs ATOS — Which Stock Is More Undervalued?

ASND scores higher with a 5.9/10 quality rating vs ATOS's 4.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Ascendis Pharma A/S (ASND) and Atossa Therapeutics, Inc. (ATOS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ASND currently trades at $237.47 with a QOC of 5.9/10, while ATOS trades at $5.19 with a QOC of 4.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).